Home

Download

Statistics

Landscape

Help

Contact

	Gene summary
	Datasets with differential expression of this gene
	Expression of this gene in the resistant group across all datasets and cell types
	Significant ligand-receptor pairs related to this gene (This gene does not contain this module)
	Known drug resistance mechanisms of this gene (This gene does not contain this module)
	MicroRNAs (miRNAs) regulating this gene
	Motifs and transcription factors (TFs) regulating this gene
	Acts as a transcription factor (This gene does not contain this module)
	Acts as a drug target< (This gene does not contain this module)

Gene: PIM2

Summary for PIM2

Gene information	Gene symbol	PIM2
	Ensembl ID	ENSG00000102096
	Entrez ID	11040
	Gene name	Pim-2 proto-oncogene, serine/threonine kinase
	Synonyms	NA
	Gene type	protein_coding
	UniProtAcc	Q9P1W9

Top

Dataset with differentially expressed gene: PIM2

Differentially expression genes between the resistant and sensitive groups. A positive avg_log2FC represents significantly high expression in the resistant group, while a negative avg_log2FC represents significantly low expression in the resistant group.

Dataset	Source	Tissue	Cancer type level1	Cancer type level2	Drug type	Regimen	Timepoint	Cell type	avg_log2FC	p_val_adj
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	Plasma cells	0.554201	9.74e-05
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	CD4+ T cells	0.389521	1.40e-45
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	Plasma cells	0.450666	8.26e-08
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	CD4+ T cells	0.303289	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	Plasma cells	0.472434	4.62e-30
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	B cells	0.3095	8.53e-24
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Neutrophils	-0.382324	3.54e-08
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD4+ T cells	0.53669	1.09e-11
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Plasma cells	1.33923	5.93e-10
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	B cells	0.475343	4.17e-06
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	pre	CD4+ T cells	0.268055	2.54e-31
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD4+ T cells	-0.592392	2.67e-16
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	pDCs	1.06667	4.90e-02
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Neutrophils	0.553974	3.37e-13
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	Malignant cells	-0.994906	0.00e+00

Top

Expression of PIM2 in the resistant group across all datasets and cell types

Red dots represent significantly high expression in the resistant group, while blue dots represent significantly low expression in the resistant group. White dots represent that there is no significant difference in the expression of this gene between the resistant and sensitive groups. Blank represents that this cell type is not present in this dataset. (If the image exists, the user can click on it to enlarge it in a new window.)

Top

Significant ligand-receptor pairs related to PIM2

This table shows the significant ligand-receptor pairs related to this gene across all datasets, timepoints and conditions. (Complete files can be downloaded from the download section.)

Top

Known drug resistance mechanisms of this gene

This table shows the known drug resistance mechanisms of this gene. Clicking on this gene will link to another database that displays more drug resistance-related information.

Top

MicroRNAs (miRNA) regulating PIM2

This table shows the miRNAs with a score of more than 80 regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	miRNA	Score	GeneBank accession
PIM2	hsa-miR-3119	96.2706	NM_006875
PIM2	hsa-miR-24-3p	95.7545	NM_006875
PIM2	hsa-miR-6734-3p	94.0351	NM_006875
PIM2	hsa-miR-3654	93.3086	NM_006875
PIM2	hsa-miR-135a-5p	91.9826	NM_006875
PIM2	hsa-miR-135b-5p	91.9826	NM_006875
PIM2	hsa-miR-548p	91.9643	NM_006875
PIM2	hsa-miR-1229-3p	88.9303	NM_006875
PIM2	hsa-miR-4673	88.1667	NM_006875
PIM2	hsa-miR-200b-3p	88.0196	NM_006875
PIM2	hsa-miR-200c-3p	88.0196	NM_006875
PIM2	hsa-miR-4699-3p	87.2703	NM_006875
PIM2	hsa-miR-548t-3p	87.2347	NM_006875
PIM2	hsa-miR-548ap-3p	87.2347	NM_006875
PIM2	hsa-miR-548aa	87.2347	NM_006875
PIM2	hsa-miR-429	87.2338	NM_006875
PIM2	hsa-miR-4256	87.031	NM_006875
PIM2	hsa-miR-11181-5p	87.031	NM_006875
PIM2	hsa-miR-4768-3p	86.8834	NM_006875
PIM2	hsa-miR-378d	86.2067	NM_006875
PIM2	hsa-miR-378f	86.2067	NM_006875
PIM2	hsa-miR-378e	86.2067	NM_006875
PIM2	hsa-miR-378b	86.2067	NM_006875
PIM2	hsa-miR-378a-3p	86.2067	NM_006875
PIM2	hsa-miR-378c	86.2067	NM_006875
PIM2	hsa-miR-378h	86.2067	NM_006875
PIM2	hsa-miR-422a	86.2067	NM_006875
PIM2	hsa-miR-378i	86.2067	NM_006875
PIM2	hsa-miR-4516	85.1904	NM_006875
PIM2	hsa-miR-3192-5p	84.676	NM_006875
PIM2	hsa-miR-4645-5p	83.7716	NM_006875
PIM2	hsa-miR-3692-3p	83.4037	NM_006875
PIM2	hsa-miR-6754-3p	83.1106	NM_006875
PIM2	hsa-miR-412-3p	83.1106	NM_006875
PIM2	hsa-miR-361-3p	82.8575	NM_006875
PIM2	hsa-miR-940	82.371	NM_006875
PIM2	hsa-miR-3661	82.3036	NM_006875
PIM2	hsa-miR-6887-3p	81.1232	NM_006875
PIM2	hsa-miR-505-3p	80.5142	NM_006875

Page: 1

Top

Motifs and transcription factors (TFs) regulating PIM2

This table shows the Motifs and transcription factors (TFs) regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	motif	TF_highConf
PIM2	transfac_pro__M05805	ZNF546 (directAnnotation).
PIM2	transfac_pro__M02082	ISL2 (directAnnotation).
PIM2	metacluster_58.12	BATF; FOSL1; FOSL1 (directAnnotation).
PIM2	transfac_pro__M06020	ZBTB40 (directAnnotation).
PIM2	transfac_pro__M06985	BATF3 (directAnnotation).
PIM2	taipale_tf_pairs__TEAD4_TBX21_ANGTGTGAATWCY_CAP_repr	TBX21; TEAD4 (directAnnotation).
PIM2	taipale_cyt_meth__CREB1_NTGACGCGTCAN_eDBD_repr	CREB1 (directAnnotation).
PIM2	metacluster_168.1	ZSCAN16 (directAnnotation).
PIM2	hdpi__KLF4	KLF4 (directAnnotation).
PIM2	transfac_pro__M05952	ZNF672 (inferredBy_Orthology).
PIM2	dbtfbs__TGIF2_HepG2_ENCSR993LMB_merged_N1	TGIF2 (directAnnotation).
PIM2	transfac_pro__M02832	ZNF410 (inferredBy_Orthology).
PIM2	hdpi__ZNF695	ZNF695 (directAnnotation).
PIM2	swissregulon__mm__Zbtb12	ZBTB12 (inferredBy_Orthology).
PIM2	transfac_pro__M06887	HINFP (directAnnotation).
PIM2	tfdimers__MD00524	NR3C1; SMAD4 (directAnnotation).
PIM2	c2h2_zfs__M0393	KLF9 (inferredBy_Orthology).
PIM2	hocomoco__TGIF1_HUMAN.H11MO.0.A	TGIF1 (directAnnotation).
PIM2	transfac_public__M00040	ATF2 (directAnnotation).
PIM2	transfac_pro__M05647	ZNF875 (directAnnotation).
PIM2	metacluster_70.14	POU2F3 (directAnnotation).
PIM2	metacluster_160.7	ZSCAN21 (directAnnotation).
PIM2	metacluster_70.7	POU3F3 (inferredBy_Orthology).
PIM2	kznf__ZNF124_Imbeault2017_RP_RCADE	ZNF124 (directAnnotation).
PIM2	metacluster_29.2	BCL6; IRF3; IRF3; STAT1; STAT1; STAT1; STAT2; STAT3; STAT3; STAT3; STAT4; STAT4; STAT5A; STAT5A; STAT5A; STAT5A; STAT5B; STAT5B; STAT5B; STAT6 (directAnnotation). STAT3; STAT5A; STAT5A; STAT5A; STAT5A; STAT5A; STAT5B; STAT5B; STAT6; STAT6 (inferredBy_Orthology).
PIM2	transfac_pro__M07066	STAT6 (directAnnotation).
PIM2	jaspar__MA1625.1	STAT5B (inferredBy_Orthology).
PIM2	transfac_pro__M06378	ZNF562 (directAnnotation).
PIM2	transfac_pro__M06731	ZNF302 (directAnnotation).
PIM2	metacluster_142.4	POU2AF1; POU2F1; POU2F1; POU2F1; POU2F1; POU2F1; POU2F1; POU2F1; POU2F1; POU2F1; POU2F1; POU2F1; POU2F2; POU2F2; POU2F2; POU2F2; POU2F2; POU2F2; POU2F2; POU2F2; POU2F2; POU2F2; POU2F2; POU2F2; POU2F3; POU2F3; POU2F3; POU2F3; POU2F3; POU3F1; POU3F2; POU3F3; POU4F1; POU5F1; POU5F1; POU5F1; POU5F1B; POU5F1B; POU5F1B; TBP (directAnnotation). CCDC160; CCDC160; CCDC160; CCDC160; CCDC160; POU2F2; POU2F2; POU2F2; POU2F2; POU2F2; POU2F2; POU2F2; POU3F1; POU3F1; POU3F1; POU3F1; POU3F1; POU3F3; POU3F3; POU3F3; POU3F3; POU3F3; POU3F3; POU3F4; POU5F1; POU5F1; POU5F1; POU5F1; POU5F1; POU5F1; POU5F1; POU5F1B; POU5F1B; POU5F1B; POU5F1B; POU5F1B; POU5F1B; POU5F1B; POU5F1B; POU5F2; POU5F2; POU5F2; POU5F2; POU5F2 (inferredBy_Orthology).
PIM2	metacluster_26.7	MYNN; MYNN (directAnnotation).
PIM2	metacluster_38.3	STAT6; STAT6 (directAnnotation). STAT6; STAT6 (inferredBy_Orthology).
PIM2	metacluster_70.1	POU5F1 (directAnnotation).

Page: 1 2

Top

Acts as a transcription factor

This table shows that this differential gene acts as a transcription factor.

Top

Acts as a drug target

This table shows that this differential gene acts as a drug target.

1	"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2	"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."